CBP/p300-IN-20 

CBP/p300-IN-20 is a potent and selective p300/CBP inhibitor, with a pIC₅₀ of 10.1 for p300. CBP/p300-IN-20 can be used for the research of cancer^[1].

CBP/p300-IN-20 (compound 28) decreases Myc protein in cell-based cMyc HTRF assay, with a pEC₅₀ of 8.5^[1].
CBP/p300-IN-20 (1 μM) shows 97% inhibition for p300 and 80% inhibition for CPB^[1].
CBP/p300-IN-20 (0.3-1000 nM; 2 h) decreases H3K18 and H3K27 acetylation without affecting H3K9 acetylation and total H3 in COLO 320HSR cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CBP/p300-IN-20 (compound 28) (0.54 mg/kg; i.v.) exhibits C_max (210 ng/mL), AUC_0→∞ (102 h•ng/mL), CL (95 mL/min/kg), and T_1/2 (0.3 h) in rats^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

477.87

C₂₂H₁₉ClF₃N₅O₂

O=C([C@@H]1N(C(C2(CC(F)(F)C2)C3=CC=C(Cl)C=C3)=O)C[C@H](F)C1)NC4=CC=C5NN=CC5=N4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Tian X, et, al. Discovery of Proline-Based p300/CBP Inhibitors Using DNA-Encoded Library Technology in Combination with High-Throughput Screening. J Med Chem. 2022 Nov 10;65(21):14391-14408.  [Content Brief]